Interventional device developer Boston Scientific has received reimbursement approval from the French government for its Taxus Express2 paclitaxel-eluting coronary stent system.
The approval enables patients to be treated with the Taxus stent system in private clinics and hospitals. The product was previously available in France primarily through public hospitals, said the company.
France represents the second largest market in Europe for coronary artery stents, with approximately 150,000 stents implanted annually. Of these, 55% are implanted in private clinics and hospitals and 45% in public hospitals, according to Natick, MA-based Boston Scientific.
By AuntMinnie.com staff writersJanuary 29, 2004
Related Reading
Boston Scientific shows uptick in preliminary 2003 results, January 14, 2004
Boston Scientific, NitroMed extend collaboration, January 8, 2004
Boston Scientific gets CE Mark for Liberte, December 30, 2003
Grissom named as Boston Scientific VP, December 10, 2003
Boston Scientific gets panel nod for Taxus, November 21, 2003
Copyright © 2004 AuntMinnie.com
